Ticagrelor
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ST Elevation Myocardial Infarction
Conditions
ST Elevation Myocardial Infarction
Trial Timeline
Jan 30, 2017 → Nov 30, 2019
NCT ID
NCT03145194About Ticagrelor
Ticagrelor is a phase 2 stage product being developed by AstraZeneca for ST Elevation Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT03145194. Target conditions include ST Elevation Myocardial Infarction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03492931 | Phase 1 | Completed |
| NCT03145194 | Phase 2 | UNKNOWN |
| NCT02341729 | Approved | Completed |
| NCT02292277 | Pre-clinical | Completed |
| NCT02282332 | Approved | Completed |
| NCT02071212 | Phase 2 | Completed |
| NCT01870921 | Approved | Completed |
Competing Products
8 competing products in ST Elevation Myocardial Infarction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Butylphthalide + Butylphthalide placebo | CSPC Pharmaceutical Group Limited | Phase 3 | 76 |
| Tirofiban + Ticagrelor | AstraZeneca | Phase 3 | 77 |
| Ticagrelor orodispersible tablets + Ticagrelor standard tablets | AstraZeneca | Phase 3 | 77 |
| Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd) | AstraZeneca | Approved | 85 |
| ticagrelor + clopidogrel | AstraZeneca | Approved | 85 |
| Ticagrelor + Clopidogrel | AstraZeneca | Approved | 85 |
| Evolocumab 140 MG/ML + Standard of care (SOC) | Amgen | Approved | 84 |
| dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) | Shenzhen Salubris Pharmaceuticals | Pre-clinical | 22 |